Premium
Dipeptidyl Peptidase IV in Human T Lymphocytes
Author(s) -
SCHÖN E.,
DEMUTH H.U.,
EICHMANN E.,
HORST H.J.,
KÖRNER H.J.,
KOPP J.,
MATTERN T.,
NEUBERT K.,
NOLL F.,
ULMER A. J.,
BARTH A.,
ANSORGE S.
Publication year - 1989
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.1989.tb01108.x
Subject(s) - lymphokine , polyclonal antibodies , dipeptidyl peptidase , peripheral blood mononuclear cell , microbiology and biotechnology , chemistry , t cell , biochemistry , antibody , enzyme , biology , immunology , in vitro , immune system
Specific inhibitors of the membrane‐bound dipeptidyl peptidase IV (DP IV) and polyclonal antibodies against this enzyme were used to investigate the relationships between DP IV activity and the production and action of T cell‐derived lymphokines. Production of interleukin 2 (IL‐2) and gamma interferon by mitogen plus phorbol ester‐simulated mononuclear cells Bran human blood was found to be reduced in the presence of N‐Ala‐Pro‐O‐(nitrobenzoyl‐)‐hydroxylamine, epsilon‐(4′nitro) benzoxycarbonyl‐Lys‐Pro, and anti‐(DP IV) immunoglobulin in a dose‐dependent manner. Moreover, the proliferative response of mitogen‐stimulated mononuclear cells to IL‐2 is impaired in the presence of DP IV inhibitors. Therefore it is suggested that the membrane peptidase DP IV is involved in the induction and activation of cytokines controlling lymphocyte proliferation